Transaction #25462 · Form 4 · 0001140361-25-046786
Roivant Sciences Ltd. · Exercise / conversion · Common Shares
Roivant Sciences Ltd. · Transacted December 24, 2025 · Filed December 29, 2025
What does this filing report?
An SEC Form 4 filing for Roivant Sciences Ltd. records an exercise / conversion involving Common Shares on December 24, 2025. The reported quantity was 117,848. The filing date is December 29, 2025. This is one transaction record; amounts are not allocated among any joint reporting owners.
The acquisition category describes how securities were received. It does not by itself establish a cash purchase of common stock. Read the transaction code definitionsand the original filing before interpreting the amounts.
Transaction details
- Company
- Roivant Sciences Ltd.
- Company CIK
- 0001635088
- Security type
- Non-derivative
- Acquisition type
- Exercise / conversion · Code M
- Quantity acquired
- 117,848
- Reported price
- 3.85
- Reference value
- 453,714.8
- Currency
- Currency not specified
- Ownership
- Direct
- Holdings after transaction
- 1,729,597
- Ownership description
- Not reported
- SEC acceptance time
- Dec 29, 2025, 9:00 PM EST
- 10b5-1 indication
- Not indicated
Reference value is reported quantity × reported price. It is not a confirmed cash payment or an estimate of a derivative's economic value. A missing currency is not assumed to be USD.
Reporting owners
- Venker Eric ↗
President & Immunovant CEO
CIK 0001801917
These are the reporting owners named in the filing. Quantities and amounts are not allocated among co-reporters. Roles reflect this filing, not a current profile.
Company listings
The linked listing is identified separately from other current company listings.
Filing footnotes & remarks
- F1
- Represents an exercise and hold transaction, with a sale of Common Shares only to cover applicable withholding taxes and the exercise price of the stock options exercised.
- F2
- The price reported in column 4 is a weighted average price. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of Common Shares sold at each separate price within the range.
- F3
- These Common Shares were sold in multiple transactions at prices ranging from $22.25 to $22.64, inclusive.
- F4
- These Common Shares were sold in multiple transactions at prices ranging from $22.50 to $22.63, inclusive.
- F5
- Award of stock options to purchase Common Shares with a vesting commencement date of April 20, 2022. These options vest and become exercisable (i) 25% on the first anniversary of the vesting commencement date and (ii) in 36 equal monthly installments thereafter, subject generally to the reporting person's continuous service through each vesting date (unless otherwise provided in the applicable award documentation).
Footnotes are reproduced as plain text from the current source filing. For the full context, read the original SEC filing.
This record was updated Eastern Time. This is the stored record update time, not the transaction date. Report a correction.